ANIMATION

HuLuc 63

Share this article with:

PDL BioPharma asked XVIVO to show how a novel humanized antibody, HuLuc 63, appears to induce anti-tumor effects by binding to a protein expressed only on the surface of myeloma cells. This initiates antibody-dependent cytotoxic activity which targets myeloma cells while leaving healthy cells intact.

Share It:
Contact XVIVO

Client


PDL BioPharma

XVIVO has done an outstanding job for us. They engaged in our graphical design project with enthusiasm and took it to a level well beyond our imagination!

Ozgur Sahin, PI, Nanomechanical Sensing, Rowland Institute at Harvard University